Moderna Reports Unanimous FDA Panel Backing for Flu Vaccine
MT Newswires Live
Jun 19
Moderna (MRNA) said Thursday an advisory committee of the US Food and Drug Administration voted in favor of the benefit-risk profile of mRNA-1010, a seasonal influenza vaccine candidate.
The Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mRNA-1010 outweigh its risks in adults 50 through 64 years and also in 65 years and older, it said.
The FDA will consider the recommendations of the committee as part of its biologics license application review for mRNA-1010, the firm said. The FDA must review the application by Aug. 5.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.